| 摘要 |
A method used for assessing the probability of survival of a cancer patient by assaying one or more ex-vivo samples from that patient, wherein the (SEQ ID NO. 37, 38) ERBB2 status of that patient is determined to be positive or negative; characterized in that in (SEQ ID NO. 37, 38) ERBB2-positive patients, at least one of a first set of cancer related genes is analysed in the sample or in one of the samples from said patient, and in (SEQ ID NO. 37, 38) ERBB2-negative patients, at least one of a second set of cancer related genes is analysed in the sample or in one of the samples from said patient.
|
